Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2024; . Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2024 Oct;5(10): . [Article]; Kirby RS, Fitzpatrick JM JM, Clarke
by JM Molero 2024 Cited by 13Keywords: Paxlovid, Nirmatrelvir / ritonavir, Drug interactions, COVID-19, Drugs that are contraindicated or should be used with or
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2024; . Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
Substance use - prescription drugs. Substance use disorder - prescription drugs; Substance abuse - prescription drugs; Drug Weiss RD, Liebschutz JM.
JM De Guzman recalls his drug relapse in 2024: 'I was imprisoned by pain and hate'
Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Testani JM, Brisco MA, Turner JM
by JM Meyer 2024 Cited by 3Current Psychiatry. 2024;16(12):. , ,47,A. Drug Brand Names.
by JM Meyer 2024 Cited by 3Current Psychiatry. 2024;16(12):. , ,47,A. Drug Brand Names.
See contract arrangements in Chapter 8.
JM